Oral News and Research

RSS

Tianyin Pharmaceutical's Qionglai Facility completes official GMP site visit by CFDA

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that its Qionglai Facility (QLF) has successfully completed the official site visit by the China Food & Drug Administration's (CFDA) for its Good Manufacturing Practice (GMP) certification.

29 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Study findings underscore huge public health challenge posed by severe periodontitis

The International and American Associations for Dental Research (IADR/AADR) have published a paper titled "Global Burden of Periodontitis: A Systematic Review and Meta-Regression."

29 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Brident Dental & Orthodontics expands operations with a new office in Houston area

Brident Dental & Orthodontics expanded its operations in the Houston area with the opening of its new office at 8201 W. Sam Houston Parkway.

29 Sep 2014

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

MicroBiome TherapeuticsTM LLC, today reported positive topline results from a proof of concept study testing whether its investigational drug, NM 505, can improve the tolerability of metformin, the first-line therapy for Type 2 diabetes worldwide.

26 Sep 2014

Antacids linked to reduced erlotinib efficacy

Acid suppression therapy may negatively impact outcome among patients receiving erlotinib for advanced non-small-cell lung cancer, Canadian study findings show.

24 Sep 2014

Alectinib promise for crizotinib-resistant NSCLC

Alectinib has shown promising antitumour activity in patients with ALK-rearranged non-small-cell lung cancer that is resistant to crizotinib, researchers report.

23 Sep 2014

Trauma center in Pennsylvania granted Level IV Trauma Center Accreditation status

Level IV Trauma Center Accreditation status has been granted to an additional hospital in Pennsylvania for the period from November 1, 2014 through October 31, 2015.

23 Sep 2014

New evidence-based guidelines for prevention, treatment of POAF

The American Association for Thoracic Surgery has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation (POAF) and flutter for thoracic surgical procedures.

23 Sep 2014

Viewpoints: CHIP funding needed; GOP's flawed plan to make 'the pill' OTC; millennials' health issues

Federal financing for a beneficial health insurance program for low-income children, known as the Children's Health Insurance Program or CHIP, will run out next year unless Congress agrees to extend it. Bills are pending in both the House and the Senate to extend financing for four years, to 2019. Congress should approve the extension in the lame-duck session after the midterm elections so that families and state officials will know what the future holds. The program needs to be maintained amid uncertainty as to whether other good coverage will be available for these children (9/21).

23 Sep 2014

Oxabact now recognized as potential treatment for Short Bowel Syndrome

SBS is a highly disabling malabsorptive condition. SBS is associated with significant morbidity and mortality, reduced quality of life and high healthcare costs.

23 Sep 2014

Highlights: Hawaii public hospital cuts; La. struggles with state worker health program costs; aging in Ky.

Public hospitals across Hawaii are finding ways to reduce staff and cut services because they don't have enough money to make ends meet. Executives from the Hawaii Health Systems Corp. told lawmakers Friday that even after layoffs they are facing a $30 million deficit in 2015. One hospital on Maui chose to close its adolescent psychology unit because it couldn't sustain the appropriate staffing levels to provide the services. It's also considering cuts to oncology and dialysis services if the situation doesn't improve (9/20).

23 Sep 2014

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).

23 Sep 2014

Consensus statement on adequate bowel cleansing for colonoscopy

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task force on Colorectal Cancer.

22 Sep 2014

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

In anticipation of next year's premium announcements and given some information already made public, concerns have surfaced about the potential for double-digit percent increases in nongroup and small-group health insurance premiums. This analysis shows that, although average annual increases in small-group premiums over the past 13 years averaged roughly 5.5 percent, double-digit average premium increases are common for states and large metropolitan areas.

22 Sep 2014

Oral News and Research

Tianyin Pharmaceutical's Qionglai Facility completes official GMP site visit by CFDA

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Study findings underscore huge public health challenge posed by severe periodontitis

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Brident Dental & Orthodontics expands operations with a new office in Houston area

MicroBiome Therapeutics' NM 505 drug can improve tolerability of metformin

Antacids linked to reduced erlotinib efficacy

Alectinib promise for crizotinib-resistant NSCLC

Trauma center in Pennsylvania granted Level IV Trauma Center Accreditation status

New evidence-based guidelines for prevention, treatment of POAF

Viewpoints: CHIP funding needed; GOP's flawed plan to make 'the pill' OTC; millennials' health issues

Oxabact now recognized as potential treatment for Short Bowel Syndrome

Highlights: Hawaii public hospital cuts; La. struggles with state worker health program costs; aging in Ky.

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Consensus statement on adequate bowel cleansing for colonoscopy

Research roundup: Home health nurses' workloads; readmissions at the VA; SHOP choices

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

Fast decline in insulin sensitivity seen in pre-diabetic South Asians

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News